12:00 AM
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Aranesp darbepoetin alfa: Development discontinued

Kyowa said in its 2012 earnings that in September it discontinued development of Aranesp in India, which included an open-label, Indian Phase III trial in 126 dialysis patients with renal anemia. The company...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >